Ailse Oncology Ltd has translational and clinical development expertise across a wide range of solid tumours and haematological malignancies and works with the pharmaceutical/ biotechnology industry, medical charities and academia in Europe, North America and Asia.
Managing Director: Glen Clack MD MB BS FFPM
Honorary Professor of Translational Medicine, Department of Oncology and Metabolism, Faculty of Medicine, University of Sheffield
Current and Previous Roles of Glen Clack
Translational and early clinical development of anti-cancer agents, from lead optimisation to clinical proof of concept in solid and haematological malignancies; both as monotherapy and combination with other anti-cancer treatments including small molecules, chemotherapy, radiotherapy and immune oncology agents.
The relevant biological effect areas of these compounds have included hormone manipulation, invasion, DNA damage repair, immune modulation, angiogenesis, MTOR/PI3K/AKT and MET pathways, anti-sense oligonucleotide, and tumour genetic drivers.
This includes the overall clinical, scientific & value content, risk benefit assessment and delivery of the medical science components to the projects to time & quality, the translational and clinical strategy, ethical and scientific integrity of the plans, studies and the product, and the risk management plan.
2020-Present
Chief Medical Officer
Modulus Oncology Ltd.
2020-Present
Oncology Drug Development Advisor
Cumulus Oncology Ltd.
2015-Present
Managing Director
Ailse Oncology Ltd., Lyme Green, Cheshire
Please fill in the contact form and we will get back to you as soon as possible.
Ailse Oncology Ltd
First Floor, Merchant Exchange
Waters Green
Macclesfield
Cheshire SK11 6JX
United Kingdom
IPSE member